Filing Details
- Accession Number:
- 0001493152-22-009000
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-04-04 16:05:36
- Reporting Period:
- 2022-03-31
- Accepted Time:
- 2022-04-04 16:05:36
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
876343 | Lineage Cell Therapeutics Inc. | LCTX | Biological Products, (No Disgnostic Substances) (2836) | 943127919 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1310683 | M Brian Culley | 2173 Salk Avenue, Suite 200 Carlsbad CA 92008 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Shares, No Par Value | Acquisiton | 2022-03-31 | 15,450 | $0.00 | 96,730 | No | 4 | M | Direct | |
Common Shares, No Par Value | Disposition | 2022-03-31 | 5,343 | $1.54 | 91,387 | No | 4 | F | Direct | |
Common Shares, No Par Value | Acquisiton | 2022-03-31 | 6,400 | $1.53 | 97,787 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | F | Direct | |
No | 4 | P | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Shares | Restricted Stock Units | Disposition | 2022-03-31 | 15,450 | $0.00 | 15,450 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
15,450 | No | 4 | M | Direct |
Footnotes
- Shares earned by the reporting person as a result of the vesting of a portion of restricted stock units ("RSUs") granted to the reporting person on September 17, 2018. RSUs convert into common shares on a one-for-one basis.
- Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this report or shares that may be acquired upon the exercise of stock options outstanding as of the date of this report.
- Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction.
- The price reported is a weighted average. The shares were purchased in multiple transactions at prices ranging from not less than $1.52 to not more than $1.54. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.
- The reporting person was granted RSUs on September 17, 2018, that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter.